参芪扶正注射液联合化疗治疗非小细胞肺癌疗效系统评估

Efficacy of Shenqi fuzheng injection in treatment of non-small cell lung cancer： a meta-analysis

目的从循证医学的角度综合分析参芪扶正注射液联合化疗对非小细胞肺癌患者疗效的系统评估。方法检索中国科技期刊数据库（维普资讯网）、中国学术期刊网全文数据库（CNKI），检索时间段设定为1990—2014年。可检索出关于参芪扶正注射液联合化疗对非小细胞肺癌患者疗效的文献165篇，最终6篇文献符合标准。对可纳入文献进行方法学质量评价，提取数据采用Meta分析专用软件RevManager5．2进行统计分析，对可以合并统计的数据合并OR值并计算95％a。结果本分析共纳入6个研究。参芪扶正注射液可显著提高患者生存质量（OR=3．90，95％CI：2．35～6．48，总体效应检验Z=5．25，P〈0．00001），提高化疗的近期疗效（OR=1．94，95％CI：1．30～2．90，总体效应检验z=3．25，P=0．001），降低不良反应发生率（OR=0．38，95％CI：0．23～0．64，总体效应检验z=3．66，P：0．0002）。结论参芪扶正注射液联合化疗治疗非小细胞肺癌可显著提高患者生存质量，提高化疗的近期疗效，降低不良反应发生率。

Objective To assess the efficacy of Shenqi fuzheng injection in treatment of non-small cell lung cancer （NSCLC） by meta-analysis among domestic and published pertinent articles scientifically. Methods Pertinent literatures on the relationship between Shenqi fuzheng injection and NSCLC were searched in CNKI and WeiPu Data, the searching terms ＂Shenqi fuzheng injection＂ and ＂ NSCLC＂ were used. According to the inclusion and exclusion criteria, the data were extracted and the methodological quality was evaluated. Then the meta-analysis was conducted by RevManager 5.2 soft ware. Results Six randomized controlled trials were included. Shenqi fuzheng injection could improve the life quality of NSCLC patients （ OR= 3.90, 95 % CI ：2.35-6.48, Z = 5.25, P 〈0. 000 01）, increase the short-term effect of chemotherapy （ OR = 1.94,95% CI ： 1.30-2.90, Z = 3.25, P = 0. 001）, reduce the occurrence rate of toxic and side effects （ OR =0.38,95% CI ：0.23-0.64, Z=3.66, P =0.000 2）.Conclusions Shenqi fuzheng injection combined with chemotherapy can improve the life quality, increase the short-term effect of chemotherapy, and reduce the incidence of side effects in the treatment of NSCLC.